A. ICH risk for a patient receiving a DOACs is about 25% lower than for those receiving a vitamin K antagonist B. ICH risk for a patient receiving a DOACs is about 50% lower than for those receiving a vitamin K antagonist C. The risk for ICH is approximately equivalent for both DOACs and warfarin, but DOACs are more easily reversible D. The risk of ICH for DOACs is equivalent to that of warfarin, but mortality rates are higher E. Unsure

A. Idarucizimab is indicated for reversal of Factor Xa inhibitors, including rivaroxaban and apixaban B. Andexanet alfa is indicated only for reversal of dabigatran, which is a direct thrombin inhibitor C. Andexanet alfa is indicated for reversal of coagulation in patients treated with Factor Xa inhibitors, including rivaroxaban and apixaban D. Ciraparantag is approved for reversal of both direct thrombin inhibitors and Factor Xa inhibitors E. Unsure

A. Older age, use of a vitamin K antagonist for ≥ 3 years; evidence of major bleeding B. Older age, use of anticoagulant (warfarin or DOAC) for ≥6 months, bleeding at a critical site C. Evidence of internal bleeding, need for administration of ≥2 units of red blood cells, previous intracranial hemorrhage D. Bleeding at a critical site, hemodynamic instability, clinically overt bleeding (hemoglobin decrease or need for red blood cells) E. Unsure

A. The patient should discontinue apixaban, but does not require a reversal agent since she is hemodynamically stable and the bleeding is considered non-major. B. The patient's injury requires surgical intervention, so a prothrombin complex concentrate should be administered to reverse anticoagulation. C. The patient's injury requires surgical intervention, so the appropriate DOAC reversal agent should be administered to reverse anticoagulation. D. The patient's advanced age puts her at high risk for cardiovascular events, so the risk of using a reversal agent versus continued anticoagulation should be carefully weighed. E. Unsure

A. The patient would be classified as having a minor bleeding event so discontinuation of the rivaroxaban is the best strategy B. The patient's bleeding is considered major. Andexanet alfa would be preferred reversal strategy if available C. The patient's bleeding is considered moderate to major. Idarucizumab would be preferred reversal strategy if available D. The patient should not restart anticoagulation at any time point after management of the bleeding episode E. Unsure